LOXL2 and gastric cancer: Other selected members of this category are matrix metallopeptidase 14 (MMP14), whose serum levels are often associated with adverse survival outcomes in GC, and lysyl oxidase-like 2 (LOXL2), which mediates the progression of GC (Kasashima et al., 2014; Kasurinen et al., 2018).